Increased Hemoglobin Associated with VEGF Inhibitors in Advanced Renal Cell Carcinoma

REFERENCES

• Sukosd F., Kuroda N., Beothe T., Kaur A. P., Kovacs G. Deletion of chromosome 3p14.2-p25 involving the vhl and fhit genes in conventional renal cell carcinoma. Cancer Res 2003; 63(2)455–457
   PubMed Web of Science ®Google Scholar
• Kim W., Kaelin W. G., Jr. The von hippel-lindau tumor suppressor protein: new insights into oxygen sensing and cancer. Curr Opin Genet Dev 2003; 13(1)55–60
   PubMed Web of Science ®Google Scholar
• Escudier B., Eisner T., Staler W. M., Szczylik C., Oudard S., Siebels M., Negrier S., Chevreau C., Solska E., Desai A. A., Rolland F., Demkow T., Hutson T. E., Gore M., Freeman S., Schwartz B., Shan M., Simantov R., Bukowski R. M. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356(2)125–134
   PubMed Web of Science ®Google Scholar
• Escudier B., Pluzanska A., Koralewski P., Ravaud A., Bracarda S., Szczylik C., Chevreau C., Filipek M., Melichar B., Bajetta E., Gorbunova V., Bay J. O., Bodrogi I., Jagiello-Gruszfeld A., Moore N. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370(9605)2103–2111
   PubMed Web of Science ®Google Scholar
• Motzer R. J., Hutson T. E., Tomczak P., Michaelson M. D., Bukowski R. M., Rixe O., Oudard S., Negrier S., Szczylik C., Kim S. T., Chen I., Bycott P. W., Baum C. M., Figlin R. A. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356(2)115–124
   PubMed Web of Science ®Google Scholar
• Motzer R. J., Rini B. I., Bukowski R. M., Curti B. D., George D. J., Hudes G. R., Redman B. G., Margolin K. A., Merchan J. R., Wilding G., Ginsberg M. S., Bacik J., Kim S. T., Baum C. M., Michaelson M. D. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295(21)2516–2524
   PubMed Web of Science ®Google Scholar
• Figlin R. A., Hutson T. E., Tomczak P., Michaelson M. D., Bukowski R. M., Negrier S., Huang X., Kim S. T., Chen I., Motzer R. J. Overall survival with sunitinib versus interferon (ifn)-alfa as first-line treatment of metastatic renal cell carcinoma (MRCC). ASCO Annual Meeting Proceedings. 2008, Abstract 5024
   Google Scholar
• Bayer Pharmaceutical Sorafenib package insert. 2007
   Google Scholar
• Genentech Bevacizumab package insert March 2008
   Google Scholar
• Pfizer Sunitinib maleate package insert 2007
   Google Scholar
• Richard S., Croisille L., Yvart J., Casadeval N., Eschwege P., Aghakhani N., David P., Gaudric A., Scigalla P., Hermine O. Paradoxical secondary polycythemia in von hippel-lindau patients treated with anti-vascular endothelial growth factor receptor therapy. Blood 2002; 99(10)3851–3853
   PubMed Web of Science ®Google Scholar
• Alexandrescu D. T., McClure R., Farzanmehr H., Dasanu C. A. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib. J Clin Oncol 2008; 26(24)4047–4048
   PubMed Web of Science ®Google Scholar
• Wei K., Kuhnert F., Kuo C. J. Recombinant adenovirus as a methodology for exploration of physiologic functions of growth factor pathways. J Mol Med 2008; 86(2)161–169
   PubMed Web of Science ®Google Scholar
• Therasse P., Arbuck S. G., Eisenhauer E. A., Wanders J., Kaplan R. S., Rubinstein L., Verweij J., Van Glabbeke M., van Oosterom A. T., Christian M. C., Gwyther S. G. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92(3)205–216
   PubMed Web of Science ®Google Scholar
• Bibb J. L., Lee S., Lu D., Lee F. Increase in systolic (sbp) and decrease in diastolic blood pressure (dbp) may predict clinical benefit (cb) of bevacizumab (b) in patients (pts) with metastatic colorectal cancer (mcrc) treated with cytotoxic agents (ca). Gastrointestinal Cancers Symposium. 2007, Abstract 450
   Google Scholar
• Friberg G., Kasza K., Vokes E. E., Kindler H. L. Early hypertension (htn) as a potential pharmacodynamic (pd) marker for survival in pancreatic cancer (pc) patients (pts) treated with bevacizumab (b) and gemcitabine (g). ASCO Annual Meeting Proceedings. J Clin Oncol 2005; 23(16), Abstract 3020
   PubMed Web of Science ®Google Scholar
• Rini B., Schiller J., Fruehauf J. P., Cohen E. E., Tarazi J. C., Rosbrook B., Ricart A. D., Olszanski A. J., Kim S., Spano J. Association of diastolic blood pressure (dbp) > 90 mm hg with overall survival (os) in patients treated with axitinib (ag-013736). J Clin Oncol 2008; 26, Abstract 3543
   Web of Science ®Google Scholar
• Tam B. Y., Wei K., Rudge J. S., Hoffman J., Holash J., Park S. K., Yuan J., Hefner C., Chartier C., Lee J. S., Jiang S., Niyak N. R., Kuypers F. A., Ma L., Sundram U., Wu G., Garcia J. A., Schrier S. L., Maher J. J., Johnson R. S., Yancopoulos G. D., Mulligan R. C., Kuo C. J. Vegf modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med 2006; 12(7)793–800
   Google Scholar
• Harshman L., Kuo C. J., Srinivas S. Bevacizumab-associated erythrocytosis in metastatic renal cell carcinoma (MRCC). American Society of Clinical Oncology Annual Meeting Proceedings. 2008, Abstract 16096
   Google Scholar
• Cella D., Kallich J., McDermott A., Xu X. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 2004; 15(6)979–986
   PubMed Web of Science ®Google Scholar
• Canon J. L., Vansteenkiste J., Bodoky G., Mateos M. V., Bastit L., Ferreira I., Rossi G., Amado R. G. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 2006; 98(4)273–284
   PubMed Web of Science ®Google Scholar
• Munugalavadla V., Kapur R. Role of c-kit and erythropoietin receptor in erythropoiesis. Crit Rev Oncol Hematol 2005; 54(1)63–75
   PubMed Web of Science ®Google Scholar
• Abrams T. J., Lee L. B., Murray L. J., Pryer N. K., Cherrington J. M. Su11248 inhibits kit and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003; 2(5)471–478
   PubMed Web of Science ®Google Scholar
• Motzer R. J., Michaelson M. D., Redman B. G., Hudes G. R., Wilding G., Figlin R. A., Ginsberg M. S., Kim S. T., Baum C. M., DePrimo S. E., Li J. Z., Bello C. L., Theuer C. P., George D. J., Rini B. I. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24(1)16–24
   PubMed Web of Science ®Google Scholar
• Wilhelm S. M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., Chen C., Zhang X., Vincent P., McHugh M., Cao Y., Shujath J., Gawlak S., Eveleigh D., Rowley B., Liu L., Adnane L., Lynch M., Auclair D., Taylor I., Gedrich R., Voznesensky A., Riedl B., Post L. E., Bollag G., Trail P. A. Bay 43-9006 exhibits broad spectrum oral antitumor activity and targets the raf/mek/erk pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64(19)7099–7109
   PubMed Web of Science ®Google Scholar
• Motzer R. J., Mazumdar M., Bacik J., Berg W., Amsterdam A., Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17(8)2530–2540
   PubMed Web of Science ®Google Scholar
• Bukowski R. M., Kabbinavar F. F., Figlin R. A., Flaherty K., Srinivas S., Vaishampayan U., Drabkin H. A., Dutcher J., Ryba S., Xia Q., Scappaticci F. A., McDermott D. Randomized phase-II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007; 25(29)4536–4541
   PubMed Web of Science ®Google Scholar
• Yang J. C., Haworth L., Sherry R. M., Hwu P., Schwartzentruber D. J., Topalian S. L., Steinberg S. M., Chen H. X., Rosenberg S. A. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349(5)427–434
   PubMed Web of Science ®Google Scholar
• Choi Y. M., Shord S., Cuellar S., Villano J. Examining ethnic differences for bevacizumab-induced hypertension and proteinuria. ASCO Annual Meeting Proceedings part I. J Clin Oncol 2007; 25, Abstract 21168
   Google Scholar
• Frey M. K., Olivera N., Bogomolniy F., Dao F., Borsu L., Konner J. A., Rizvi N. A., Barakat R. R., Dickler M. N., Levine D. A. Wnk1 haplotypes and bevacizumab-induced hypertension. J Clin Oncol 2008; 26, Abstract 11003
   Web of Science ®Google Scholar
• Fischer C., Carmeliet P., Conway E. M. Vegf inhibitors make blood. Nat Med 2006; 12(7)732–734
   PubMed Web of Science ®Google Scholar
• Alexandre I., Billemont B., Meric J. B., Richard S., Rixe O. Axitinib induces paradoxical erythropoietin synthesis in metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 472–473, author reply 3–4
   PubMed Web of Science ®Google Scholar
• Van der Veldt A. A., Boven E., Vroling L., Broxterman H. J., van den Eertwegn A. J., Haanen J. G. Sunitinib-induced hemoglobin changes are related to the dosing schedule. J Clin Oncol 2009; 27: 1339–1340, author reply 40–42
   PubMed Web of Science ®Google Scholar